Oakbrook Investments LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 380,473 shares of the biopharmaceutical company’s stock after selling 5,705 shares during the period. Gilead Sciences comprises 1.8% of Oakbrook Investments LLC’s portfolio, making the stock its 16th largest position. Oakbrook Investments LLC’s holdings in Gilead Sciences were worth $26,930,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in GILD. Norges Bank acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $997,048,000. Parnassus Investments CA raised its stake in shares of Gilead Sciences by 37.4% in the first quarter. Parnassus Investments CA now owns 16,726,150 shares of the biopharmaceutical company’s stock valued at $1,110,228,000 after buying an additional 4,556,901 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Gilead Sciences by 9.8% in the first quarter. Bank of New York Mellon Corp now owns 30,570,798 shares of the biopharmaceutical company’s stock valued at $2,076,368,000 after buying an additional 2,727,063 shares during the period. Numeric Investors LLC raised its stake in shares of Gilead Sciences by 173.5% in the fourth quarter. Numeric Investors LLC now owns 2,820,505 shares of the biopharmaceutical company’s stock valued at $201,976,000 after buying an additional 1,789,101 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. raised its stake in shares of Gilead Sciences by 75.0% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after buying an additional 1,092,206 shares during the period. 74.06% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences, Inc. (GILD) traded down 1.76% during mid-day trading on Thursday, reaching $72.60. The company had a trading volume of 4,069,678 shares. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.10. The firm has a market capitalization of $94.81 billion, a P/E ratio of 7.89 and a beta of 1.21. The firm’s 50-day moving average is $72.16 and its 200-day moving average is $68.73.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. During the same period in the previous year, the firm earned $3.08 earnings per share. The company’s revenue was down 8.2% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.76 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.81%. The ex-dividend date of this dividend is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.watchlistnews.com/oakbrook-investments-llc-has-26-93-million-position-in-gilead-sciences-inc-gild/1471346.html.

Several equities research analysts have issued reports on GILD shares. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $74.58 price target on the stock in a report on Tuesday, April 18th. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target on the stock in a report on Tuesday, May 2nd. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Barclays PLC reissued an “overweight” rating and issued a $85.00 price target (down previously from $90.00) on shares of Gilead Sciences in a report on Sunday, April 23rd. Finally, Credit Suisse Group reissued an “outperform” rating and issued a $79.00 price target on shares of Gilead Sciences in a report on Monday, May 15th. Twelve investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $80.31.

In other Gilead Sciences news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.